| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.46▲ | 1.46▲ | 1.46▲ | 1.44▲ | 1.44▲ |
| MA10 | 1.45▲ | 1.45▲ | 1.44▲ | 1.46▼ | 1.46▼ |
| MA20 | 1.44▲ | 1.44▲ | 1.44▲ | 1.45▲ | 1.61▼ |
| MA50 | 1.42▲ | 1.44▲ | 1.47▲ | 1.48▼ | 1.93▼ |
| MA100 | 1.46▲ | 1.45▲ | 1.46▲ | 1.66▼ | 2.10▼ |
| MA200 | 1.46▲ | 1.50▼ | 1.57▼ | 1.96▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.004▲ | 0.005▲ | 0.003▲ | 0.002▲ |
| RSI | 59.073▲ | 57.540▲ | 55.311▲ | 49.299▼ | 42.736▼ |
| STOCH | 95.833▲ | 95.833▲ | 80.000 | 37.248 | 29.905 |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -51.282 | -59.831 |
| CCI | 127.273▲ | 123.404▲ | 96.855 | -14.316 | -79.749 |
| CDL | $BCG Doji Candlestick Pattern Detected | Set Alert |
|
Wednesday, August 26, 2026 03:49 PM
IBRX's aggressive R&D spend, weak financials, and emerging competition from TAR-200 and cretostimogene pose risks to future value realization. Click to read.
|
|
Thursday, August 13, 2026 07:57 PM
CG Oncology (CGON) advances cret for NMIBC with strong CR rates and best-in-class safety; see trial results and 2026–2027 catalysts. See more here.
|
|
Thursday, August 13, 2026 07:47 AM
BCG Leader Daniel Friedman joins Kristen Scholer on NYSE Live to discuss the M&A market after gains ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/08/26 | 1.45 | 1.46 | 1.4101 | 1.45 | 19,513 |
| 26/08/26 | 1.42 | 1.46 | 1.39 | 1.45 | 22,413 |
| 25/08/26 | 1.47 | 1.4799 | 1.41 | 1.445 | 17,453 |
| 24/08/26 | 1.45 | 1.46 | 1.435 | 1.45 | 24,991 |
| 21/08/26 | 1.38 | 1.4263 | 1.38 | 1.40 | 18,242 |
| 20/08/26 | 1.39 | 1.49 | 1.37 | 1.40 | 38,125 |
| 19/08/26 | 1.50 | 1.5099 | 1.375 | 1.39 | 84,603 |
| 18/08/26 | 1.53 | 1.555 | 1.49 | 1.50 | 30,205 |
| 17/08/26 | 1.58 | 1.58 | 1.525 | 1.56 | 47,195 |
| 14/08/26 | 1.56 | 1.58 | 1.5001 | 1.54 | 105,082 |
|
|
||||
|
|
||||
|
|